Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stephens Resumes Myriad Genetics (MYGN) at Overweight
May 9, 2013 7:53 AM EDTStephens resumed coverage on Myriad Genetics (NASDAQ: MYGN) with an Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more... More
Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 6c
May 7, 2013 4:29 PM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $148.25 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.... More
